Cited 0 times in
Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T00:52:07Z | - |
dc.date.available | 2023-06-02T00:52:07Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194484 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | P.G. Aftimos | - |
dc.contributor.googleauthor | J. Cortés | - |
dc.contributor.googleauthor | F.C. Bidard | - |
dc.contributor.googleauthor | V. Kaklamani | - |
dc.contributor.googleauthor | A. Bardia | - |
dc.contributor.googleauthor | P. Neven | - |
dc.contributor.googleauthor | G. Streich | - |
dc.contributor.googleauthor | A. Montero | - |
dc.contributor.googleauthor | F. Forget | - |
dc.contributor.googleauthor | M.A. Mouret Reynier | - |
dc.contributor.googleauthor | J. Sohn | - |
dc.contributor.googleauthor | D. Taylor | - |
dc.contributor.googleauthor | K. Harnden | - |
dc.contributor.googleauthor | H. Khong | - |
dc.contributor.googleauthor | J. Kocsis | - |
dc.contributor.googleauthor | F. Dalenc | - |
dc.contributor.googleauthor | P. Dillon | - |
dc.contributor.googleauthor | G. Tonini | - |
dc.contributor.googleauthor | K.J. Grzegorzewski | - |
dc.contributor.googleauthor | J. Lu | - |
dc.identifier.doi | 10.1016/j.annonc.2022.07.259 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S092375342202110X | - |
dc.citation.volume | 33 | - |
dc.citation.number | Suppl 7 | - |
dc.citation.startPage | S638 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Suppl 7) : S638, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.